[ORGANIZATION]
International Foundation of Employee Benefit Plans
Featured in 2 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
247 clusters · 895 sources · last updated
Latest: GLP-1 medications transform obesity treatment approach
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr
Corporate GLP-1 medication coverage trends
3 clusters · 9 sources · last updated
Latest: Bank of America maintains GLP-1 coverage for obesity
Major U.S. employers are adopting diverging strategies regarding the coverage of GLP-1 weight-loss medications, such as Ozempic, Wegovy, and Zepbound, due to rising costs. Bank of America has committed over $250 million